Novartis manufacturing facility in North Carolina gets FDA all-clear to produce, ship gene therapies
Just one day after Vas Narasimhan announced $1 billion in cuts amid a company-wide restructuring, the American-Swiss pharma received FDA clearance to produce its spinal muscular atrophy drug Zolgensma out of its North Carolina manufacturing facility.
The pharma made the announcement earlier Tuesday, which allows the massive, 170,000-square-foot facility to make the drug — along with testing and shipping it. The commercial licensure is not just limited to Zolgensma, according to Novartis — the plant will also have the ability to produce certain gene therapy products for use in clinical trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.